Journal of Mind and Medical Sciences
Volume 6 | Issue 1

Article 12

2019

Photodynamic therapy as a new therapeutic
approach of oral lichen planus
Sandra Milena Tocut
Wolfson Medical Center, 61 Halochamim Street, 58100, Holon, Israel

Madalina Irina Mitran
Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021, Bucharest, Romania

Cristina Iulia Mitran
Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021, Bucharest, Romania

Mircea Tampa
Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021, Bucharest, Romania,
tampa_mircea@yahoo.com

Maria Isabela Sarbu
Carol Davila University of Medicine and Pharmacy, 37 Dionisie Lupu, 020021, Bucharest, Romania
See next page for additional authors

Follow this and additional works at: https://scholar.valpo.edu/jmms
Part of the Dermatology Commons, and the Digestive, Oral, and Skin Physiology Commons

Recommended Citation
Tocut, Sandra Milena; Mitran, Madalina Irina; Mitran, Cristina Iulia; Tampa, Mircea; Sarbu, Maria Isabela; Popa, Gabriela Loredana;
and Georgescu, Simona Roxana (2019) "Photodynamic therapy as a new therapeutic approach of oral lichen planus," Journal of Mind
and Medical Sciences: Vol. 6 : Iss. 1 , Article 12.
DOI: 10.22543/7674.61.P6471
Available at: https://scholar.valpo.edu/jmms/vol6/iss1/12

This Review Article is brought to you for free and open access by ValpoScholar. It has been accepted for inclusion in Journal of Mind and Medical
Sciences by an authorized administrator of ValpoScholar. For more information, please contact a ValpoScholar staff member at scholar@valpo.edu.

Photodynamic therapy as a new therapeutic approach of oral lichen planus
Authors

Sandra Milena Tocut, Madalina Irina Mitran, Cristina Iulia Mitran, Mircea Tampa, Maria Isabela Sarbu,
Gabriela Loredana Popa, and Simona Roxana Georgescu

This review article is available in Journal of Mind and Medical Sciences: https://scholar.valpo.edu/jmms/vol6/iss1/12

Copyright © 2019. All rights reserved
https://scholar.valpo.edu/jmms/
https://proscholar.org/jmms/
ISSN: 2392-7674

J Mind Med Sci. 2019; 6(1): 64-71
doi: 10.22543/7674.61.P6471

Received for publication: June 29, 2018
Accepted: September 10, 2018

Review
Photodynamic therapy as a new therapeutic
approach of oral lichen planus
Sandra Milena Tocut1, Madalina Irina Mitran2, Cristina Iulia Mitran2, Mircea
Tampa2,3, Maria Isabela Sarbu2, Gabriela Loredana Popa2, Simona Roxana
Georgescu2,3
1

Wolfson Medical Center, 61 Halochamim Street, 58100, Holon, Israel
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
3
Victor Babes Clinical Hospital for Infectious Diseases, Bucharest, Romania
2

Abstract

Oral lichen planus (OLP) is a chronic, immunologically mediated disease, defined by
periods of exacerbation and quiescence. The disease is associated with a low mortality
risk, but in some instances, morbidity can be important, especially in extensive, erosive
forms, with a significant impact on the quality of life.
OLP is a chronic T-cell mediated inflammatory disease involving the oral cavity, the
most common lesions being located on the oral mucosa, tongue and gums. Its etiology
remains in part unknown, but several factors proved to be involved in the development of
the disease (drugs, dental materials, infectious agents, psychological factors,
autoimmunity and genetic predisposition).
The therapeutic approach should take into account the type of lesion and the extent of
the disease, as well as the possible adverse effects. Although several therapies are
available, OLP treatment still remains a challenge. Photodynamic therapy (PDT) is
widely used in dermatology, finding applicability in the treatment of an increasing
number of conditions. Recent research has shown the role of PDT in the treatment of
OLP. It is a minimally invasive therapy with few side effects and promising results.
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Introduction
Oral lichen planus (OLP) affects 0.5-2% of the general
population (1). OLP is a chronic T-cell mediated
inflammatory disease involving the oral cavity, the most
common lesions being located on the oral mucosa, tongue
and gums. Its etiology remains unknown, but several
factors proved to be involved in the development of the
disease including drugs, dental materials, infectious
agents, psychological factors, autoimmunity and genetic
predisposition (2-5). There are numerous studies attesting
the role of hepatitis C virus infection in the pathogenesis
of OLP; the presence of viral RNA was revealed in the
samples from the oral mucosa of OLP patients (6). It
seems that lymphocytes, the main cells involved in the
pathogenesis of OLP, are activated under the action of an
internal or external factor, which will lead to the release
of high amounts of mediators of inflammation, resulting
in the apoptosis of keratinocytes (7-9).
From a clinical point of view, several forms of OLP
have been described, namely reticular, papular, plaquelike, atrophic, bullous and erosive. The atrophic, erosive
and bullous forms associate pain as the main symptom,
which is often a therapeutic challenge (10). Several
therapies are available, but none is curative. The most
important objective of the therapy should be the reduction
of the inflammatory process and consequently, the
alleviation of pain (11). Topical corticosteroids (with
moderate or high potency) are the first-line treatment in
OLP, systemic corticosteroids being recommended only
in severe or non-responsive cases to topical therapy as
well as in cases when the patient associates cutaneous
lesions (12). The most important side effect of local
steroid therapy is oral candidiasis; therefore, it is often
recommended to associate corticosteroids with an
antifungal drug. The atrophy of the oral mucosa has rarely
been reported (11).
In chronic cases, when corticosteroids are used for
long periods of time, although the level of absorption is
low, there is a risk of adrenal suppression; therefore, these
patients should be carefully monitored (13). Other topical
therapeutic options are calcineurin inhibitors and
retinoids.
Immunosuppressant
drugs
including
methotrexate, cyclosporine and azathioprine have also
been used (1, 13). Since OLP lesions resistant to
corticosteroids have been reported, it is necessary to use
other therapies. In this context, several authors have
studied the efficacy of photodynamic therapy (PDT) in

OLP treatment. It seems that PDT is effective in the
treatment of OLP by inducing the apoptosis of
inflammatory cells, which are the most important players
in OLP pathogenesis (14).

Discussions
The psychological impact of oral lichen planus on
the patient’s life quality
Disorders of the oral cavity are associated with a
significant impact on the patient’s life quality. Fadler et
al. conducted a study on 149 patients and evaluated the
psychological impact of oral mucosal disorders. They
found that bullous diseases of the oral mucosa and OLP
had had the greatest impact (15). Radwan-Oczko et al.
analyzed 42 OLP patients with a mean duration of the
disease of 43 months. Several questionnaires were used in
order to assess the impact of OLP on the patients’ life
quality. There was a positive correlation between the
duration of the disease and the level of perceived stress
and a negative correlation between the duration of the
disease and the quality of life (16).
Lopez-Jornet et al. demonstrated that psychological
discomfort and social disability are increased in OLP
patients (17). Another recent study showed that
psychiatric disorders such as anxiety and depression are
more common among these patients (18). Moreover,
Karbach et al. compared OLP patients with those with
oral cancer and identified a higher pain score of the
lesions and a lower social disability score among OLP
patients (19). A study revealed that the degree of stress is
higher among patients with erosive OLP than among
those with non-erosive OLP (20). Interestingly enough, a
case control study evaluated the psychological profile of
OLP patients and highlighted that low self-control and
depression are more strongly associated with mild forms
of OLP (reticular and papular) than with severe forms.
This might have a role in the progression of OLP lesions
(21).
Stress seems to contribute to the development of OLP
lesions (22). It has been suggested that the oral mucosa
has increased reactivity to psychological stimuli (23).
Stress, both acute and chronic, induces changes in the
immune response. However, it should be taken into
account that the disorder itself is a stressful factor for the
patient (24).
Photodynamic therapy – a promising therapy
Photodynamic therapy is a therapeutic approach that is
increasingly used in a broad spectrum of disorders. In
dermatology, there are various diseases that may benefit
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from this therapy (25-27). In 1900, the medical student
Oscar Raab and his professor Von Tappeiner described
PDT as an antimicrobial therapy, observing Paramecium's
photoinhibition. They noticed that acridine, which is
chemically inert under dark conditions, is activated by
sunlight leading to the destruction of the Paramecium
species (28, 29). In 1999, the FDA approved PDT in the
treatment of precancerous lesions of the face and scalp (3032). PDT has the advantage of being a minimally invasive
technique that preserves the normal tissue (33, 34).
PDT can be regarded as a particular form of
photochemotherapy, based on a photochemical reaction,
which uses a photosensitizer, a source of light and
oxygen, exerting a selective cytotoxic effect (35, 36). The
activation of the photosensitizer by light results in the
generation of reactive oxygen species, especially singlet
oxygen, leading to tissue necrosis and apoptosis (37, 38).
The main steps of the technique include the
administration of the photosensitizing agent, which will
accumulate selectively in the target cells, followed by the
illumination of the respective area with a light source.
Numerous light sources are employed in PDT, including
coherent and non-coherent light sources. The main
sources that can be used are ultraviolet light (330-400
nm), red light (600-700 nm) and near infrared light (700100 nm). Longer wavelength light penetrates deeper into
the tissue (33). Most of the photosensitizers are activated
at a wavelength between 630-700 nm (39).
A series of photosensitizers have been used in time,
initially systemically and then topically. Nowadays, 5aminolevulinic acid (ALA) remains one of the most used
topical agents. ALA is endogenously converted into
protoporphyrin IX, a photosensitizing molecule, which
leads to the formation of reactive oxygen species after
exposure to an appropriate wavelength (400-410 nm, 635
nm) (40). Besides ALA, one of the most used agents is its
derivative, methyl aminolevulinate (MAL) (41). Other
photosensitizers are phenothiazines such as toluidine blue
and methylene blue (620-700 nm) that are especially used
in dentistry (39).
In most cases, PDT is well tolerated, the main side
effects being pain, erythema and, in some cases, urticaria.
Scar formation or other allergic reactions may occur less
frequently (42, 43).
The role of photodynamic therapy in oral lichen planus
The results of the studies on PDT efficacy in the
treatment of OLP, are heterogeneous. This can be
explained by the fact that different photosensitizers (ALA,
methylene blue, toluidine blue, etc.) and various light
sources (diode laser, light emitting diode) are employed
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(44). Grandi et al. reviewed the data on the efficacy of
PDT in OLP therapy. They analyzed one case series, three
prospective single-arm and five open-label randomized
clinical trials and noticed that a wide range of
photosensitizers and different modalities to evaluate the
patients were used. The analysis concluded that beneficial
effects of PDT were observed in all studies, but the
overall response rate varied between 0 and 29%. There
were no notable side effects during the treatment. Grandi
et al. draw attention to the fact that the effects of PDT
might increase weeks or months after application, thus the
follow-up period is very important and could have
repercussions on the outcomes of the studies (45).
A systematic review by Akram et al. on the role of
PDT in OLP treatment showed that none of the analyzed
studies evaluated histopathological changes after PDT. In
addition, the authors pointed out that the assessment of
PDT efficacy is difficult given that there is no consensus
on the parameters which should be used and in most
studies the follow-up period was too short. Furthermore,
they emphasized the need to compare the results with a
control group consisting of patients treated with
corticosteroids (46).
The meta-analysis by Jajarm et al. focused on
comparing the effectiveness of corticosteroid therapy with
new phototherapy methods including low-level laser
therapy and PDT. They observed that low-level laser
therapy is effective in relieving pain and clinical signs.
However, there were no differences when these two
parameters were analyzed in comparison with the results
obtained in patients treated with corticosteroids. Lowlevel laser therapy was superior to corticosteroids only
when the effect on the severity of lesions was evaluated.
With respect to the reduction in size of OLP lesions,
similar results were obtained when PDT was compared
with corticosteroids (47).
Methylene blue-mediated PDT
Methylene blue is an agent that has been used in
medicine for over 100 years. It is used in various diseases
such as methemoglobinemia or urolithiasis; the compound
has low toxicity on human tissue. It is best absorbed at
wavelengths higher than 620 nm (48). Aghahosseini et al.
evaluated the efficacy of PDT in OLP in a study that
included 26 lesions from 13 patients with
histopathologically confirmed OLP, refractory to previous
treatments, including topical application of corticosteroids
or cyclosporine. They used 5% methylene blue as a
photosensitizer and the irradiation was performed using
light laser with a wavelength of 632 nm. An improvement
was obtained for 16 lesions. The mean reduction in lesion

Sandra Milena Tocut et al.
size was 44.3% at 12 weeks after the therapy. Favorable
results have also been obtained regarding the pain level
(49). Another recent study using methylene blue as a
photosensitizer and a light source with a wavelength of
630 nm included 20 OLP patients. After 4 sessions, 10
patients experienced a moderate improvement and the rest
of the patients were unresponsive. Moreover, they
evaluated the patients two weeks after therapy and
observed that the lesions significantly improved in 5
patients, 12 underwent moderate improvement and 3 were
unresponsive. The results were significantly better four
weeks after the therapy, a fact which indicated that the
PDT effect should also be quantified during follow-up
visits (50).
Bakhtiari et al. evaluated the efficacy of methylene
blue-mediated PDT in comparison with topical steroid
therapy in 30 patients diagnosed with erosive or reticular
OLP. In the corticosteroid group, 0.5 mg dexamethasone
solution was used in 5cc water. They showed that PDT is
as effective as the dexamethasone solution in the OLP
treatment (51). Mostafa et al. also compared the efficacy
of methylene blue-mediated PDT with corticosteroids in
patients with erosive OLP. They included 10 OLP
patients treated with topical corticosteroids and 10 OLP
patients treated with PDT in the study (the light source
used was 630 nm diode laser). In patients treated with
PDT, a greater reduction in the pain level and lesion size
was observed when compared to the corticosteroid group.
Therefore, the authors concluded that PDT is more
effective than steroid therapy, having the role of reducing
pain, thus alleviating a symptom (52). Regarding the
efficacy of topical corticosteroids versus laser
phototherapy, Akram performed a systematic review in
order to determine whether the efficacy of low-level laser
therapy is higher compared to topical corticosteroids in
OLP patients. Five studies were included, in 3 of them
topical corticosteroids were superior to low-level laser
therapy, one study revealed greater improvement using
low-level laser therapy and one showed similar results
between the studied groups. These heterogeneous results
denote that further studies are needed (53).
ALA-mediated PDT
ALA interacts with the light source and leads to the
release of reactive oxygen species (54, 55). It is a secondgeneration photosensitizer, synthesized in the laboratory,
acting as a prodrug, with a good specificity for tumor
tissue (56).
A recent study used ALA to assess the efficacy of
PDT in the treatment of OLP. The complete resolution of
lesions was achieved in 50% of cases and a partial

response in 35.7% of them. The symptoms (pain,
discomfort during speech) disappeared in all patients (57).
The study conducted by Sulewska et al., which included
50 patients with reticular OLP, evaluated 5% ALA PDT
(the illumination source was represented by a diode lamp
with a high-power LED emitting light at 630 nm), over a
period of 10 weeks, one session per week. Out of the 124
lesions, 46 were completely healed. At the end of the
therapy, the mean reduction in size of the lesions was
62.91%, and after 12 months, 78.7% respectively (58).
Rakesh et al. highlighted the utility of PDT in the case of
10 patients with relapsing erosive OLP. They used 4%
ALA and red light (wavelength of 600-670 nm). Gingival
lesions had the poorest response (59).
PDT was employed in the treatment of premalignant
oral lesions (60). Thus, the study conducted by Maloth
included 13 patients with oral leukoplakia and 8 patients
with OLP. Regarding oral leukoplakia, PDT led to lesion
resolution in 16.6% of patients and 66.6% of them
observed partial resolution, the rest of the patients did not
respond to therapy. In the case of OLP patients, 80% had
a partial response and 20% had no response. They used
ALA and blue light with a wavelength of 420 nm. The
study also compared PDT with conventional therapy, and
better results were achieved when PDT was used in
patients with oral leukoplakia; however, in the case of
OLP the results were similar (61). A systematic review
evaluated the available data on the efficacy of PDT in
premalignant
lesions,
including
leukoplakia,
erythroplakia,
erythro-leukoplakia
and
verrucous
hyperplasia. Thirteen trials were analyzed and the number
of the studied patients ranged from 5 to 147. The
complete response to PDT varied between 27% and
100%. No response to PDT was recorded in 0 - 25% of
cases (62).
Kvaal et al. studied the efficacy of MAL-PDT (red
light at a wavelength of 600 to 660 nm) on 17 patients
with OLP. One side of the mouth was treated with MALPDT and the other side was considered the control side.
The improvement of the lesions was achieved after a
single session and there was a long-term effect, the
patients being followed-up for 4 years (63).
Other photosensitizers
Jajarm et al. analyzed the efficacy of PDT using
toluidine blue as a photosensitizer in comparison with
topical corticosteroids in OLP patients, with the erosiveatrophic form. No significant differences were found
when the sign scores of changes were compared between
the two groups. However, better results have been
obtained regarding the improvement of the symptoms and
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efficacy indices in the patients treated with
corticosteroids. Additionally, the rate of relapse was
lower among these patients (64). The study by Mirza
analyzed toluidine blue-mediated PDT, using GaAlAs
laser with 630 nm wavelength and low-level laser
therapy, using diode laser with wavelength of 630 nm in
comparison with conventional corticosteroid therapy in
patients with OLP. A total of 45 patients were divided
into 3 groups. Group 1 was treated with toluidine bluemediated PDT, group 2 with low-level laser therapy and
group 3 performed 5-minute rinses with dexamethasone.
The results highlighted the favorable effects of PDT and
laser therapy, but corticosteroids were more effective on
pain relief. The authors concluded that corticosteroids
remain the gold standard in OLP therapy (65).
Sobaniec et al. used chlorine e6 (Photolon®)
consisting of 20% chlorine e6 and 10% dimethyl
sulfoxide, as a photosensitizer, and a semiconductor laser
with a wavelength of 660 nm. The patients underwent 10
sessions at a 2-week interval. Among the 23 patients, 48
lesions were identified and treated. The mean reduction in
lesion size was 55% and 14 lesions were completely
healed. Better results were obtained for lesions localized
on the cheeks and lips, compared to those on the tongue
and gums (66).

Conclusions
The therapeutic approach in OLP still remains a
challenge. Although several therapies are available, none
of them can be considered the ideal therapeutic approach.
PDT seems to be a promising therapy; however, the
results are heterogeneous. This is the result of a lack of
standardization, the available studies using different
sources of light, wavelengths and photosensitizers.
Further studies are needed to determine which parameters
are optimal in order to achieve the best results.
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